P427 Impact of curcuma longa on clinical activity and inflammatory markers in patients with active ulcerative colitis: a double-blind randomised placebo-controlled trial

BackgroundCurcumin, biologically active substance of Curcuma longa (CL), has been shown to reduce disease activity in patients with ulcerative colitis (UC). However, role of natural CL in patients with active UC is not known. We conducted study to know the effect of CL in reducing clinical activity and inflammatory markers in patients with active UC.